Home › NCT07144813
Post-Approval Study of the Neuspera Sacral Neuromodulation System
Clinical Post- Approval Study of the Neuspera Sacral Neuromodulation (SNM) System in Patients With Symptoms of Urinary Urgency Incontinence (UUI)
Who can join
Ages 22 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Subjects in the SANS-UUI Phase I or Phase II study Exclusion Criteria: * None
About the study
Prospective, multi-center, single-arm, post-approval study is designed to assess the long-term safety and efficacy data of the Neuspera Sacral Neuromodulation (SNM) System following commercial approval of the Neuspera SNM System.
Participants in this study received intervention/implanted in Phase I or Phase II of the Neuspera SANS\_UUI (NSM-004) Study.
What is being tested
- Neuspera Implantable Sacral Neuromodulation System (device)
Sponsor: Neuspera Medical, Inc. · Participants: 116 · Started: Sep 3, 2025
Contact the study team
- Mark Vollmer · Phone: 408-433-3839
- Shital Patel · Phone: 323-528-1320
Official record on ClinicalTrials.gov — NCT07144813
Locations in the U.S.
| Texas | Urology Austin,, Austin |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.